Imagine a young girl facing cancer treatment. She is scared not just of the disease, but of losing her ability to have children later. A new look at data from a Swedish hospital asks if a simple blood test can warn us before that loss happens. The team measured a hormone called anti-mullerian hormone, which acts like a count of the eggs left in a woman's ovaries.
They followed 74 girls diagnosed with pediatric cancer. Some had not started treatment yet, while others were already receiving chemotherapy or radiotherapy. The results were clear: girls who had received treatment had hormone levels 79% lower than those who had not. Their hormone levels ranged from very low to nearly 10, showing a wide difference between the two groups.
This study is still in its early stages, gathering baseline data as the girls grow up. The researchers plan to check these hormone levels every two years until the patients are about 25 years old. While no safety problems were reported in this first look, the study has not yet proven that this test can predict the future for every patient. It is a starting point to find who might benefit from saving their fertility before treatment begins.
